![](/img/cover-not-exists.png)
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
Kedar V. Inamdar, Jorge E. Romaguera, Elias Drakos, Ronald J. Knoblock, Mar Garcia, Vasiliki Leventaki, L. Jeffrey Medeiros, George Z. RassidakisVolume:
115
Year:
2009
Language:
english
Pages:
10
DOI:
10.1002/cncr.24506
File:
PDF, 389 KB
english, 2009